Bionano Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq drops as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
- Hertz cuts guidance, announces notes and stock offerings, shares sink
Bionano Genomics (BNGO) PT Lowered to $8 at Ladenburg Thalmann
March 2, 2022 7:45 AM ESTLadenburg Thalmann analyst Jeffrey Cohen lowered the price target on Bionano Genomics (NASDAQ: BNGO) to $8.00 (from $9.50) while maintaining a Buy rating following results.
The analyst commented, "Bionano announced Q4- and FY-2021 financial results and held a conference call to discuss. For the... More
BioNano Genomics, Inc. (BNGO) Reports Q4 Net Loss of $29.5M
March 1, 2022 4:13 PM ESTBioNano Genomics, Inc. (NASDAQ: BNGO) reported Q4 net loss of $29.5M. Revenue for the quarter came in at $6.3 million versus the consensus estimate of $5.57 million.
GUIDANCE:
BioNano Genomics, Inc. sees FY2022 revenue of $24-27 million.
For earnings history and earnings-related data on BioNano Genomics, Inc. (BNGO) click here.
... More